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Abstract
Macrolides including azithromycin (AZM) can improve clinical symptoms in
asthma regardless of infection status. The mechanisms underlying these benefi-
cial effects are yet to be elucidated. The aim of this study was to determine the
effect of AZM on the airway epithelial barrier both in an in vitro model and in
patients with asthma. Primary human bronchial epithelial cells (HBEC) were
grown at air liquid interface (ALI) and challenged using lipopolysaccharides
from Pseudomonas aeruginosa. AZM was added at various stages and barrier
integrity assessed using transepithelial electrical resistance (TEER) and perme-
ability to FITC-dextran. MMP-9 levels were measured using ELISA. AZM
enhanced barrier integrity (TEER/FITC-dextran), increased thickness, sup-
pressed mucin production, and MMP-9 release during the formation of a nor-
mal epithelial barrier in vitro. MMP-9 levels inversely correlated with TEER.
AZM also enhanced maintenance of the barrier and facilitated repair post-LPS
challenge. To provide translation of our findings, 10 patients with moderate-
severe asthma were recruited and received 250 mg AZM o.d for 6 weeks. Bron-
chial biopsies taken pre- and post-AZM treatment did not show evidence of
increased epithelial barrier thickness or decreased mucin production. Similarly,
bronchial wash samples did not show reduced MMP-9 levels. Overall, our data
show that AZM can significantly improve the development of a normal bron-
chial epithelial barrier in vitro, mimicking reepithelization postinjury. AZM also
suppressed MMP-9 release which correlated with barrier integrity, suggesting a
putative mechanism. However, these effects were not observed in biopsy sam-
ples from asthma patients treated with AZM, possibly due to small sample size.
Introduction
Azithromycin (AZM) is a broad-spectrum antibiotic that
can improve clinical outcomes in various respiratory dis-
eases, regardless of infection status (Hahn et al. 2012;
Spagnolo et al. 2013). Clinical benefits in asthma include
improvements in: symptoms, peak expiratory flow, quality
of life, and airway hyper-responsiveness (AHR) (Reiter
et al. 2013). Azithromycin may also prevent exacerbations
in severe noneosinophilic asthma (Brusselle et al. 2013),
chronic obstructive pulmonary disease (Albert et al.
2011), cystic fibrosis (CF) (Wolter et al. 2013), and non-
CF bronchiectasis (Wong et al. 2012). Mechanistic inves-
tigations of AZM report extended nonantibiotic
properties including: antiinflammatory (Zimmermann
et al. 2009), immunomodulatory (Shinkai et al. 2008)
and antiviral actions (Gielen et al. 2010; Schogler et al.
2015), reduced mucin production (Ribeiro et al. 2009),
and suppression of matrix metalloproteinases (MMP)-2
and -9 (Murphy et al. 2007).
Asthma is a chronic inflammatory disease of the air-
ways characterized by AHR and episodes of cough,
breathlessness, and wheezing. It is thought that a dysfunc-
tional epithelial lining of the airways is associated with
the pathogenesis of asthma, leading to penetration of
inhaled particles, bronchoconstriction, and inflammation
(Holgate 2007). Chronic inflammation and bronchocon-
striction are also thought to drive airway remodeling
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(Grainge et al. 2011), which may lead to fixed airflow
obstruction. Therefore, treatments which enhance epithe-
lial barrier integrity could help reduce infiltration of
inhaled particles and inflammation leading to clinical
benefit in asthma.
Modification of the bronchial epithelium has been pre-
viously reported in vitro, where addition of AZM to
immortalized bronchial epithelial cell cultures influenced
epithelial integrity (Asgrimsson et al. 2006). However, the
effect of AZM on reepithelization, a key mechanism
thought to be important in epithelial damage and repair,
has not been investigated. Although macrolides improve
symptoms and other measures of airway dysfunction in
asthma (Reiter et al. 2013), the effect of AZM on struc-
tural cells of the airways and whether any effect on struc-
tural cells could be linked to clinical benefit, is unclear.
Therefore, we hypothesized that AZM may enhance
epithelial barrier integrity in vivo, contributing to the
clinical benefits of AZM therapy observed in asthma.
The aim of this study was therefore to investigate the
effects of AZM on human bronchial epithelial cell func-
tion in vitro and determine if these findings are also
observed in the airways of asthma patients treated with
AZM, that is, provide direct translation of our in vitro
findings.
Materials and Methods
Cell culture
Normal healthy human bronchial epithelial cells (HBEC)
(Lonza CloneticsTM, Basel, Switzerland) and a bronchial
brush sample from a healthy volunteer (see clinical study
for ethics details) were grown at ALI (Stewart et al.
2012a,b). The cells were from three donors; all male, Cau-
casian, aged 19, 22, and 43 years. Briefly, cells were
thawed and seeded into T75 cm2 flasks at a density of
3500 cells/cm2 in full growth media ([bronchial epithelial
growth medium [BEGM, Lonza], consisting of bronchial
epithelial basal medium [BEBM, Lonza]) plus
SingleQuots bullet kit (13 mg/mL bovine pituitary
extract, 2 mL 0.5 mg/mL hydrocortisone, 0.5 mL 0.5 lg/
mL hEGF, 0.5 mL 0.5 mg/mL epinephrine, 0.5 mL
10 mg/mL transferrin, 0.5 mL 5 mg/mL insulin, 0.5 mL
0.1 lg/mL retinoic acid, 0.5 mL 6.5 lg/mL triiodothy-
ronine, 0.5 mL 50 lg/mL gentamicin and amphotericin
B, 0.5 mL). Fresh medium was added after 24 h and then
every 2 days until 90% confluent. Media was changed
after subculture to bronchial epithelial differentia-
tion media (BEDM) consisting of 1:1 BEBM (Lonza):Dul-
becco’s modified eagle’s media (DMEM) (Sigma-
Adrich) + SingleQuots (Lonza) excluding triiodothy-
ronine and retinoic acid, with 50 nmol/L final
concentration of retinoic acid supplemented at time of
addition. Passage 3 cells were seeded into transwells
(0.4 lm pore size, 6.5 mm diameter, 0.33 cm2 growth
area, Corning Life Science) at a density of 4 9 10⁴ cells
in 200 lL BEDM per transwell. When cells were conflu-
ent, BEDM was removed from the apical (upper) com-
partment, cells washed with warm sterile phosphate-
buffered saline (PBS), and media replaced in the basolat-
eral (lower) compartment only from that time onwards.
AZM dihydrate (Pfizer Inc., New York, NY) was dissolved
in 100% ethanol to 12.5 mg/mL and further diluted in
culture medium at time of addition. AZM, vehicle, or
media was added to the basolateral chamber at various
times during cultures.
Transepithelial electrical resistance
measurements
Transepithelial electrical resistance (TEER) was measured
using the EVOM2 Voltohmeter with STX2 chopstick elec-
trodes (World precision Instruments, Stevenage, UK) as
directed by the manufacturer. Media was aspirated and
cells were washed apically with PBS to remove mucus. A
quantity of 200 lL apical and 500 lL basolateral BEDM
was added to each transwell and cells were left to equili-
brate at 37°C and 5% CO2 for 20 min before readings
were taken. TEER measurements were corrected using
transwell inserts with no cells (subtracted from each mea-
surement) and values were corrected to filter size.
Fluorescein isothiocyanate (FITC)-dextran
transport assay
Barrier permeability was measured by adding 200 lL of
1 mg/mL 4 kDa FITC-dextran (Sigma) diluted in bron-
chial epithelial basal cell media (BEBM, Lonza) to the
apical surface of cells with 500 lL basolateral BEBM.
After 24 h, transwells were removed and basolateral
supernatants were transferred to a clear bottom black 96-
well plate and measured in triplicate (485 nm excitation,
530 nm emission).
Immunofluorescence
Transwells were washed in PBS, fixed in 4% formalde-
hyde, and stored at 4°C. Cells were blocked and perme-
abilized using 1% BSA +10% Goat serum in 0.15%
Triton X-100 in PBS for 1 h and then incubated with
anti-MUC5AC monoclonal IgG antibody (Sigma) over-
night at 4°C. Secondary antibody was then added 1:100
(Goat anti-mouse IgG, Alexfluor488 [Invitrogen/Life
Technologies, Paisley, UK]) for 1 h at room temperature.
Transwells were mounted with DAPI fluorescent
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mounting media (Vector Laboratories Ltd., Peterborough,
UK) and left overnight at 4°C before analysis using a
spinning disk confocal microscope with Volocity software
(Version 5.5, PerkinElmer, Cambridge, UK).
Clinical study
Ten participants with moderate-severe asthma were
recruited in this study (Tables 1 and 2), which was per-
formed in accordance to the Declaration of Helsinki with
ethical approval (reference 11/EM/0062), Clinical Trials
Register EudraCT: 2011-000237-36. Participants gave
written consent for clinical assessments and broncho-
scopies both pretreatment (visit 1) and posttreatment
(visit 2), following 250 mg daily open-label AZM (Zithro-
max, Pfizer Inc.) for 6 weeks. Patients had no clinical sign
of infection and had not received antibiotics for 6 weeks.
Bronchoscopy procedure
Endobronchial biopsies were obtained using standard
procedures (du Rand et al. 2013; Shaw et al. 2015).
Table 1. Inclusion and exclusion criteria for azithromycin in asthma (AZA) clinical study.
Inclusion Criteria Exclusion criteria
• Male or female aged between 18 and 80 years old
• Clinical diagnosis of refractory asthma
• Symptomatic despite receiving treatment at step 4 of the BTS asthma guidelines:
evidence of poor asthma control in terms of regular night-time awakening (>2/week)
or more than four puffs of relief medication/day (>twice/week) requiring repeated
(two or more per year) courses of oral corticosteroids despite treatment with
high-dose inhaled corticosteroids (≥1000lg beclomethasone or equivalent) and
treatment with, or a previous unsuccessful trial of, a long-acting beta-agonist or
leukotriene antagonist
• Pregnant females
• Inadequate contraception
or lactation
• Antibiotic course within the
last 6 weeks
• Smoking history in excess
of 20 pack years
• Clinical diagnosis of allergic
bronchopulmonary aspergillosis
• Bronchiectasis
• Abnormal liver function tests
• History of liver disease
• Medication known to interact
with azithromycin (e.g., ciclosporin,
digoxin, ergot derivatives,
terfenadine, warfarin, antacids, and ritonavir)
Table 2. Asthma patient demographics at recruitment.
Subject Age Gender Other morbidities Current treatments Juniper ACQ score % predicted FEV1
01 51 M Sinus polyps Carbicysteine, Salbutamol,
Symbicort
0.17 (+) 53
02 48 F Pacemaker Phyllocontin, Salbutamol, Singulair,
Symbicort
4.17 () 64
03 63 M Sinusitis Prednisolone, Salbutamol, Seretide 0.67 (+) 54
04 58 F None Phyllocontin, Prednisolone, Singulair,
Symbicort, Terbutaline
3.67 () 58
05 20 F None Atrovent, Phyllocontin, Prednisolone, Salbutamol,
Seretide, Tiotropium
2.67 () 81
06 62 M Gout, sinus polyps Salbutamol, Seretide, Singulair 1.17 (+/) 80
07 57 F Diabetes Salbutamol, Seretide, Singulair 2.00 () 90
08 19 F None Singulair, Symbicort 0.50 (+) 67
09 36 F None Phyllocontin, Prednisolone, Symbicort 1.67 () 90
10 46 F Depression Fostair 2.50 () 43
Ten subjects with asthma were recruited meeting inclusion criteria. F = female/M = male, ACQ, asthma control questionnaire; (+), adequate
asthma control according to ACQ scores (≤0.75); (), inadequate asthma control (≥1.5); (+/), the cross-over between adequate and inade-
quately controlled asthma; FEV1, forced expiratory volume in 1 sec.
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Samples from asthma patients both pretreatment (visit 1)
and posttreatment (visit 2) were collected.
Hematoxylin and eosin (H&E) staining and
assessment of barrier thickness
Transwells containing cells treated for 14 days AZM
were washed in media and then 3 9 15 min in PBS.
These were then fixed in 4% formaldehyde and paraffin
embedded. Mounted sections of biopsies or transwells
were sectioned and stained with H&E or alcian blue.
Mounted sections were imaged using a Nikon light
microscope with 409 objective Nikon UK Limited, King-
ston upon Thames, UK. Barrier thickness was assessed in
four separate wells per condition from two different
HBEC donors (n = 4) or all biopsies available. Three
images were taken from three different sections and three
measurements were made at one quarter, one half, and
three-quarter intervals by setting a scale using the width
of the transwell filter (10 lm) with Image J software
(Version1.45s, National Institute of Health, Bethesda,
MD). Cell nuclei were counted in each image and
expressed as cells per 100 lm length of transwell.
MMP-9 measurements
Active MMP-9 was measured using a Fluorokine E assay
(R&D Systems, Abingdon, UK) following manufacturer
recommendations. MMP-9 was normalized to total pro-
tein in bronchial washes via Bradford assay.
Statistical analyses
PRISM software (Version6.03, GraphPad Software Inc., La
Jolla, CA) was used for statistical analyses. Two-way
ANOVA compared differences over time compared with
controls. All data were analyzed using nonparametric anal-
yses: Wilcoxon sign-rank test for paired and Mann–Whit-
ney test for unpaired analyses and Kruskal–Wallis test for
multiple comparisons. Spearman’s correlation assessed the
relationship between outcome measures. A P < 0.05 was
considered significant.
Figure 1. Azithromycin improves airway epithelial barrier formation in vitro. (A) Transepithelial electrical resistance (TEER) of media, vehicle,
and 40 lg/mL azithromycin (AZM)-treated human bronchial epithelial cells (HBEC) at air liquid interface (ALI) over 14 days (n = 15). (B) Area
under the curve analysis of (A). (C) TEER of vehicle, AZM (0.4–40 lg/mL)-treated HBEC at ALI day 14 alone (n = 5). (D) Absorbance of
fluorescein isothiocyanate (FITC)-dextran from HBEC in figure (C). Figure A shows median (+/IQR). Results from (B, C, and D) were normalized
to media (100%) in each experiment. Experiments from three different HBEC donors. *P < 0.05; **P < 0.01; ****P < 0.0001.
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Results
AZM improves barrier formation in
differentiating bronchial epithelial cells
To mimic bronchial reepithelization, we examined the
effect of AZM during differentiation of primary HBEC at
ALI (Fig. 1). AZM enhanced the formation of a barrier as
assessed by both TEER (Fig. 1A, B, and C) and passage of
FITC-dextran (Fig. 1D). AZM (40 lg/mL) treatment sig-
nificantly elevated TEER by day 14 (n = 15, P < 0.0001)
(Fig. 1A). Area under the curve (AUC) analysis normal-
ized to media (100%) confirmed this finding, where
AZM = 157% (138–181) versus vehicle = 97% (94–110)
(15 experiments in three donors, P < 0.0001) (Fig. 1B).
However, in titration studies, 4 or 0.4 lg/mL had no
effect on TEER (Fig. 1C). The higher dose of AZM
(40 lg/mL) significantly reduced passage of FITC-dextran
compared with vehicle, where absorbance normalized to
media (100%) in AZM-treated cells = 65% (53–71) versus
vehicle-treated cells = 95% (84–107) (P = 0.002). The
lower doses of AZM were not statistically different to
vehicle, suggesting a dose–response effect (Fig. 1D). There
was a significant correlation between TEER and FITC-
dextran permeability data in each experiment (correlation
(r) range = 0.51 to 0.79, P < 0.001), which has been
reported previously (Xiao et al. 2011).
AZM increases epithelial barrier thickness
To identify morphological changes induced by AZM on
the epithelial barrier in vitro, we measured barrier thick-
ness in ALI sections (Fig. 2). AZM treatment leads to the
formation of a thicker cellular layer in both donors, indi-
cating alterations in the morphology of the epithelial bar-
rier (Fig. 2A–F). Median barrier thickness of cells treated
with AZM, vehicle, or media alone for 14 days with IQR:
AZM = 22.0 lm (19.1–26.3), vehicle = 9.2 lm (8.1–
10.2), and media = 8.8 lm (7.7–9.0) (n = 4, P = 0.02).
When normalized to media from each experiment
(100%), barrier thickness of cells treated with
AZM = 266% (214–319) versus vehicle = 112% (95–117)
(n = 4, P = 0.014) (Fig. 2G). To further define the factors
underlying this increased barrier thickness in AZM-trea-
ted cells, that is, hyperplasia versus hypertrophy, we
determined cell numbers per 100 lm on these transwell
images. There was no significant increase in cell number
in the AZM-treated epithelial layers (Fig. 2H).
AZM suppresses mucin production
To complement and extend previous evidence that AZM
suppresses mucin production, we investigated mucin
expression in ALI sections using alcian blue staining and
MUC5AC immunofluorescence (Fig. 3). AZM treatment
resulted in the formation of an epithelial barrier with
reduced and nonuniform mucin expression, as assessed
by alcian blue staining of transwells after 14 days AZM
treatment (Fig. 3A–F). Similarly, MUC5AC immunofluo-
rescent staining of ALI day 21 cells in this model con-
firmed suppression in AZM-treated cells (Fig. 3G–L).
AZM maintains an established bronchial
epithelial cell barrier
To determine the effect of AZM on barrier integrity when
a differentiated barrier had been established, cells were
differentiated at ALI for 21 days. AZM was then added
daily for 7 days and TEER measurements were recorded
(Fig. 4A). AZM aids in barrier maintenance: median
TEER (AUC) days 21–28 with IQR, AZM = 124% (121–
138) versus vehicle = 105% (104–109) (n = 4, P = 0.03)
(Fig. 4B).
AZM pretreatment facilitates the acute
response to bronchial epithelial cell damage
To assess the response of differentiated cells to damage,
potentially mimicking respiratory infection, we investi-
gated the effect of AZM pretreatment on cell response to
LPS (P. aeruginosa). Cells grown to ALI day 21 were
pretreated AZM for 7 days, then 1 mg/mL LPS was
added apically for 24 h. TEER was read at intervals up
to 72 h. LPS addition led to a significant loss in epithe-
lial integrity as determined by a drop in TEER for all
treatment groups (Fig. 4C). However, AZM (40 lg/mL)
pretreated cells demonstrated a reestablishment of TEER
at 3 h compared with vehicle (n = 4, P < 0.01)
(Fig. 4D). Median TEER with IQR normalized to media
over 24 h; AZM = 531% (357–654) and vehicle con-
trol = 128% (107–132) (n = 4, P = 0.03) (Fig. 4E). At
24 h, this protective effect of AZM was no longer pre-
sent and all treatment groups demonstrated minimal
TEER. TEER of unchallenged controls did not drop
below baseline levels (Fig. 4C).
AZM suppresses MMP-9 levels
To assess the effect of AZM on MMP-9, levels of both
total and active MMP-9 in basolateral supernatants from
ALI experiments pretreated for 14 days AZM were
measured (Fig. 5A and B). Both total and active MMP-9
were significantly suppressed in these basolateral super-
natants following treatment with AZM (40 lg/mL). Total
MMP-9 (median relative fluorescence unit [RFU]) with
IQR normalized to media; AZM = 32% (31–36) and
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vehicle control =101% (77–110) (n = 3, P = 0.050) and
active (median RFU) with IQR normalized to media;
AZM = 50% (34–51) and vehicle control = 111% (88–
130) (n = 3, P = 0.050). There was a significant correla-
tion between total and active MMP-9 in these samples
(r = 0.84, P < 0.0001) (Fig. 5C). Similar findings were
observed in apical wash samples where total MMP-9
concentrations were significantly suppressed following
AZM treatment; AZM (median, IQR) = 16% (14–32)
and vehicle control = 86% (54–109) (n = 4, P = 0.012,
Fig. 5D).
MMP-9 levels and barrier thickness correlate
with epithelial integrity
In order to translate our morphological and secretory find-
ings that AZM significantly suppresses MMP-9 and also
leads to a significant increase to epithelial barrier thickness,
we correlated these outcomes with our primary measure of
epithelial integrity, TEER (Fig. 6). These data demonstrate
that total basolateral MMP-9 (r = 0.62 P < 0.0001),
active basolateral MMP-9 (r = 0.70 P < 0.0001), and
total apical MMP-9 (r = 0.54, P < 0.0001) all negatively
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Figure 2. Azithromycin increases airway epithelial layer thickness in vitro. Azithromycin (AZM) treatment from air liquid interface (ALI) day 0
generates a visibly thicker epithelial layer by day 14. Cells were treated for 14 days (39 weekly) at ALI with 40 lg/mL AZM, vehicle, or media,
at which time they were fixed and stained with hematoxylin and eosin. HBEC donor 1 treated with (A) 40 lg/mL AZM, (B) vehicle, and (C)
media. HBEC donor 2 treated with (D) 40 lg/mL AZM, (E) vehicle, and (F) media. Representative light microscope images (940 objective) from
four wells per condition. (G) Median epithelial barrier thickness of HBEC layer at ALI day 14 in cells treated with 40 lg/mL AZM, vehicle, or
media (thickness compared with media (100%) from each experiment, (P = 0.014, n = 4). (H) Cell counts per 100 lm transwell length were
normalized to media (100%) (P > 0.05, n = 4). NS, nonsignificant.
2016 | Vol. 4 | Iss. 18 | e12960
Page 6
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
Azithromycin, Airway Epithelial Barrier In Vitro and In Vivo M. Slater et al.
A B C
D E F
G H I
J K L
Figure 3. Azithromycin suppresses mucin production by airway epithelial cells in vitro. The effect of 40 lg/mL azithromycin (AZM), vehicle, and
media on alcian blue glycoprotein staining of ALI day 14 HBEC. Cells were treated 39 weekly for 14 days at ALI and transwells were fixed,
sectioned, stained, and imaged using a light microscope (409 objective). HBEC donor 1 treated with (A) media, (B) vehicle, and (C) AZM. HBEC
donor 2 treated with (D) media, (E) vehicle, and (F) AZM. Arrows point to dark blue staining, suggesting mucus-secreting goblet cells. Confocal
microscopy of mucin 5AC (MUC5AC) immunofluorescence of HBEC treated for 21 days at ALI for donor 1: (G) medium, (H) vehicle, and (I)
40 lg/mL AZM and donor 2: (J) medium, (K) vehicle, and (L) 40 lg/mL AZM.
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correlated with TEER (Fig. 6A–C). Similarly, epithelial bar-
rier thickness was positively correlated with TEER
(r = 0.58, P < 0.0001) (Fig. 6D).
Asthma patient studies do not translate
in vitro findings
In order to translate our in vitro finding, we investigated
the effect of AZM on the airway epithelium in vivo by
recruiting 10 asthma patients to complete a clinical study
involving 6 weeks of AZM treatment. A bronchial biopsy
at visit 1 (pre-AZM) and visit 2 (6 weeks post-AZM) was
collected. Biopsy morphology varied significantly between
patient/visit emphasizing the heterogeneity of asthma
observed in other studies (see representative Fig. 7A).
Overall, epithelial barrier thickness of asthma patient
biopsies (six per visit) did not alter post-AZM; visit
1 = 53.1 lm (35.5–70.5) versus visit 2 = 43.0 lm (37.9–
63.3) (P = 0.675) (median and range). There was also no
significant difference in epithelial thickness within each
patient between visits (Fig. 7B). Biopsies from asthma
patients were also stained with alcian blue and goblet cells
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normalized to prechallenged TEER (magnified as part of Figure Panel C) (n = 4, median with IQR). (E) Area under the curve analysis of (F)
normalized to media (100%), with median values shown. *P < 0.05; **P < 0.01; ***P < 0.001.
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were counted (Fig. 7C). Goblet cell number varied
between patient/visit: statistical analysis of five biopsies at
two visits revealed no significant difference between %
goblet cells at visit 1 (0.0% [0.0–15.8]) versus visit 2
(5.1% [0.2–11.2]), either between groups (P = 0.683) or
within each patient (P > 0.999) (median and range)
(Fig. 7D). MMP-9 levels were also measured in bronchial
washes pre- and post-AZM treatment. Analyses revealed
no significant difference between active MMP-9 within
each patient between visits (Fig. 7E and F). Furthermore,
MMP-9 levels did not correlate with epithelial biopsy
thickness (data not shown). Finally, we also determined if
AZM resulted in hyperplasia in vivo to complement our
in vitro analyses; there was no significant difference in cell
counts (per 100 lm basement membrane length) in biop-
sies from asthma patients between visit 1 (35.9 [31.2–
47.4]) and visit 2 (39.8 [29.3–48.7]) (P = 0.788) (median
and range). Pairwise analysis confirmed no significant dif-
ferences in cell counts between visits (P = 0.688, data not
shown).
Discussion
Macrolide antibiotics, including AZM, have additional
properties beyond those of an antimicrobial and show
potential utility in asthma and other airway diseases
(Richeldi et al. 2008; Hernando-Sastre 2010). However,
an underlying mechanism of action is yet to be defined.
In this study, we further define the effects of AZM on the
bronchial epithelial cell barrier, a substratified layer of
cells that is thought to be altered in asthma, using a phys-
iologically relevant in vitro model. Our data demonstrate
that AZM has multiple beneficial effects on epithelial bar-
rier properties including: (1) improved barrier formation
during differentiation, (2) improved maintenance of an
established barrier, and (3) improved response of the
epithelium to damage. Importantly, alterations in barrier
properties were functionally relevant as assessed by
permeability assays and morphological studies where
AZM-treated epithelial cell layers displayed hypertrophy,
resulting in increased barrier thickness. AZM altered the
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expression profile of the epithelial layer including sup-
pression of mucins and MMP-9 expression. Endogenous
release of MMP-9 correlated with our primary measure of
epithelial integrity (TEER), providing a putative mecha-
nism. In contrast, we did not observe significant effects
on the same series of outcomes in the bronchial epithe-
lium in vivo using samples collected pre- and post-AZM
treatment in moderate-severe asthma patients. Overall,
these data provide novel insight into the additional prop-
erties of AZM on bronchial epithelial homeostasis, which
is particularly relevant for the mechanism of action of
AZM and derivatives in respiratory disease. In addition,
this study highlights the challenge of translating in vitro
findings to the more heterogeneous in vivo setting.
There are intrinsic differences between normal and
asthmatic airway epithelium including: altered prolifera-
tion, cytokine and mucus production, susceptibility to
injury, and the ability to develop a functional epithelial
barrier (Kicic et al. 2006; Xiao et al. 2011). It has also
been reported that tight junction protein (TJP) ZO-1
and E-cadherin are expressed at lower levels in asthmatic
airways ex vivo (Holgate 2007) and that TEER is
significantly lower in ALI cultures of asthma patient cells
(Xiao et al. 2011). Therefore, improvement of the bron-
chial barrier may be a potential target for clinical benefit.
We hypothesized that AZM may influence airway epithe-
lial function as part of the beneficial effect observed
in vivo, in particular, the ability of bronchial epithelial
cells to develop, maintain, and repair a functional bar-
rier. AZM enhanced the integrity of a developing HBEC
barrier with a significant increase in TEER, barrier thick-
ness, and a reduction in permeability to FITC-dextran.
There was no effect on cell number in ALI cultures com-
pared to transwell length indicating that AZM treatment
causes HBEC dysplasia or metaplasia. These data, to the
best of our knowledge, provide the first evidence sup-
porting an effect of AZM on reepithelization of a devel-
oping epithelial barrier. This information may be
clinically relevant, that is, AZM may have greater benefits
in severe asthma where exacerbation and epithelial shed-
ding/reepithelization/differentiation are an ongoing pro-
cess. Similarly, our observation of improved epithelial
integrity post-AZM in vitro has the potential to “cor-
rect” the intrinsic defects described in asthma patient
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cells observed at ALI (Xiao et al. 2011). However, it is
important to be cautious in the interpretation of these
in vitro findings and it remains unclear if the modest
effects on barrier properties (TEER) we observed in cells
isolated from subjects without respiratory disease are
reproducible in cells from, for example, asthma patients.
Similarly, it remains unclear if these in vitro measures
truly relate to clinically relevant outcomes in patients.
Another consideration is the dramatic change in mor-
phology of the epithelial barrier induced by AZM, that
is, increased thickness. It is feasible that this anatomical
change may actually be detrimental to airway function.
These considerations were the foundation for an asthma
patient arm to this study.
In addition to improving the formation of a barrier,
AZM also promoted the maintenance of an already estab-
lished epithelial barrier. Similar improvements in TEER
have been demonstrated using the same dose of AZM
(40 lg/mL) in differentiated immortalized HBEC, with
no effect on cell proliferation, viability, or apoptosis.
AZM treatment also caused internalization of TJP occlu-
din and claudins (Asgrimsson et al. 2006). The current
and previous findings have clear inferences for the preser-
vation of epithelial barrier integrity. We also used LPS
from P. aeruginosa to mimic respiratory tract infection
leading to epithelial damage. AZM did not protect against
the initial challenge, though results indicate that AZM
helps reestablish barrier integrity compared with vehicle,
shown by increased TEER between 2 and 3 h postchal-
lenge which was maintained to at least 8 h. This informa-
tion suggests that AZM pretreatment primes cells to
respond to injury, supporting low-dose long-term therapy
which could speed up patient recovery postexacerbation.
It is important to note that this reestablishment of TEER
was lost at 24-h postinjury, indicating an acute phase
response which may be dependent upon challenge dura-
tion. Our data are in good agreement with the recent
finding that 60 lg/mL AZM was protective in human
gingival epithelial cells when challenged with TNFa,
including the maintenance of epithelial barrier (TEER)
(Miyagawa et al. 2016). This study went on to suggest
that the mechanism underlying this effect, at least in part,
involved AZM inhibiting the phosphorylation of ERK and
p38 MAP kinase in TNFa-treated cells and preventing a
decrease in E-cadherin (Miyagawa et al. 2016). A limita-
tion of this study is that we did not evaluate the effect of
AZM on these and other signaling pathways in the differ-
ent stages of the experiments, however, Miyagawa and
colleagues did not relate these signaling changes to the
primary outcome TEER leaving findings difficult to inter-
pret (Miyagawa et al. 2016). One hypothesis that we eval-
uated was the potential role of MMP-9 in these
responses.
MMP-9 is secreted by a host of cells including neu-
trophils, eosinophils, dendritic cells, and epithelial cells
and acts on fibrin, denatured collagen (gelatin), and TJP
ZO-1 as well as other substrates (Demedts et al. 2005).
MMP-9 is elevated in severe acute asthma (Lemjabbar
et al. 1999; Belleguic et al. 2002), during exacerbations of
asthma (Oshita et al. 2003), and postallergen challenge
(Kelly et al. 2000). MMP-9 gene deletion attenuates aller-
gic asthma in a mouse model (Vermaelen et al. 2003) fur-
ther suggesting its role in asthma and airway remodeling.
MMP-9 specifically deregulates TJP and increases the per-
meability of macromolecules in differentiated HBEC (re-
versible on tissue inhibitor of metalloproteinase [TIMP]1
addition) (Vermeer et al. 2009). Macrolides are known to
suppress MMPs at both the gene and protein levels both
in vitro and in vivo (Simpson et al. 2008; Ribeiro et al.
2009; Verleden et al. 2011). Therefore, we hypothesized
that MMP-9 suppression by AZM in our experiments
may at least in part underlie the beneficial effects
observed on integrity. We reproduced and extended pre-
vious work to show that AZM suppresses both total and
active MMP-9, but demonstrate for the first time that
endogenous release of MMP-9 directly correlates with
barrier integrity, providing a putative mechanism. While
a limitation of this study was that we did not add exoge-
nous MMP-9 in an attempt to reverse the beneficial
effects of AZM, others have shown that recombinant
MMP-9 added to the epithelial ALI model results in a sig-
nificant loss of epithelial integrity (measured by TEER),
TJP localization, and permeability to macromolecules
(Vermeer et al. 2009). Importantly, MMP-9 suppression
has been demonstrated in vivo in BAL samples taken
from lung transplant patients post-AZM treatment sup-
porting our in vitro observations (Verleden et al. 2006).
The finding that AZM suppresses MMP-9 has implica-
tions for targeting treatment to multiple lung conditions
and warrants further investigation both in vitro and
in vivo.
In bronchial epithelial cells cultured from asthma
patients, there is a reported increase in mucin production
(Holgate 2007), including MUC5AC. Our data support
previous findings (Ribeiro et al. 2009) demonstrating that
HBEC pretreated with AZM for 14 and 21 days results in
a complete suppression of mucin production leading to
negligible staining with alcian blue and MUC5AC com-
pared with controls. Mucus is required for clearance of
inhaled particles in the lung, but can exacerbate airway
obstruction; this may be important in fatal asthma where
mucus plugging has been described (Bai and Knight
2005). Therefore, in addition to the beneficial effects of
AZM on epithelial integrity and MMP-9, mucin suppres-
sion is also considered a clinically relevant property.
While we did not define the mechanism underlying the
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suppression of MUC5AC by AZM, a recent study has
shown that AZM can suppress MUC5AC (and MUC2) in
HBECs stimulated with IL-13 at the mRNA and protein
levels and suggested a mechanism involving chloride
channel accessory 1 (CLCA1) (Mertens et al. 2016).
CLCA1 has been shown to be elevated in the airway
epithelium in asthma (Woodruff et al. 2009) and linked
to MUC5AC expression (Kim et al. 2007; Mishina et al.
2015). A role for AZM suppression of extracellular signal-
regulated kinase (ERK) 1/2 and I-kappa B phosphoryla-
tion has also been suggested to contribute to MUC5AC
suppression (Imamura et al. 2004). Overall, these data
suggest that further investigation of the effect of AZM on
mucin production and also goblet cell hyperplasia and
metaplasia are warranted with potential implications for
multiple diseases where mucus hypersecretion is a feature.
While our in vitro data are compelling regarding the
additional properties of AZM on bronchial epithelial cell
homeostasis including barrier properties and secretory
profile, we set out to translate these finding to the in vivo
situation. Our initial aim was to recruit 10 eosinophilic
asthma patients and 10 neutrophilic asthma patients,
based on the ability to detect a 0.5 difference in the Juni-
per asthma control score (ACQ), with 80% power. How-
ever, we could not recruit to target and we had a
significant drop out rate as not all patients tolerated the
first bronchoscopy. This left 10 asthma patients to com-
plete a clinical study involving 6 weeks of AZM treatment
with six patients providing both pre- and post-AZM sam-
ples for analyses. Examination of bronchial biopsies from
10 moderate-severe asthma patients treated 250 mg daily
open-label AZM (Zithromax, Pfizer Inc.) for 6 weeks did
not identify any significant change in: (1) bronchial
epithelial cell thickness, (2) mucin production (% goblet
cells), and (3) MMP-9 production (bronchial wash) when
pre- and post-AZM samples were compared. Data gener-
ated for each of these outcomes were highly heteroge-
neous, potentially as anticipated for an in vivo study
using relatively small numbers of recruited patients which
may have limited our ability to observe measurable effects
of AZM.
Similarly, it is difficult to compare the in vitro situa-
tion where bronchial epithelial cells will have a sustained
AZM exposure in contrast to the in vivo epithelium
were exposure is difficult to evaluate. A key limitation
of our study was that we used cells from subjects with-
out respiratory disease (e.g., not asthma patients) to
investigate AZM in vitro and then used asthma patients
to try reproduce these observations in vivo. This relies
on the assumption that bronchial epithelial cells isolated
from control or asthma patients respond in the same
way, which at this time we cannot answer. Similarly, the
beneficial effects of AZM have been observed in
respiratory disease patients again making the assumption
that control/disease cells behave the same without foun-
dation. Therefore, these data can be considered prelimi-
nary in nature and do not support or refute the effects
of AZM observed in the in vitro experiments. Overall,
AZM was well tolerated during this short study, as pre-
viously reported (Hahn et al. 2012), and while not a
primary objective of the study, it is important to note
that 4/10 asthma patients had an improvement in
asthma symptoms (Asthma Control Questionnaire
[ACQ] using previously reported thresholds [Juniper
et al. 2005]). These data also illustrate the heterogeneity
in the patient responses to AZM. However, overall, we
did not observe similar effects on the bronchial epithe-
lium as in vitro potentially due to the limitations of our
study outlined.
This study is the first of its kind to directly relate labo-
ratory findings with in vivo findings in relation to the
epithelium in asthma. We have demonstrated for the first
time that AZM significantly improves the development of
a normal bronchial epithelial barrier in vitro, mimicking
reepithelization postinjury. Similarly, we demonstrated
the effects on maintenance of a barrier and the ability of
the epithelial barrier to repair postchallenge. AZM sup-
pressed MMP-9 release which correlated with barrier
integrity, suggesting a putative mechanism. In the clinical
arm of the study, we did not observe significant effects of
AZM on the bronchial epithelium in vivo. Our current
findings support the development of AZM derivatives that
maintain the potentially useful “extended” properties of
the drug, but lack antibiotic properties and also other
strategies targeting airway epithelial integrity. This study
also emphasizes the challenge of directly translating
in vitro finding to patients and the need for larger in vivo
mechanistic studies.
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